petosemtamab
merus
['potentia', '$mrus']
$mrus #aacr23 - robust 36% overall response rate (orr) in 42 evaluable patients
- 6 months median duration of response with 17 patients still on treatment as of nov. 28, 2022 data cutoffend-of-phase meeting with fdaprovides clarity to potentialregistration 
BIOTECH man LONGTERM FOCUS many positions-also trade around my CORE holdings my opinion only do your own research with me